- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc stock price live, this page displays NASDAQ SPRY stock exchange data. View the SPRY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ARS Pharmaceuticals Inc real time stock price chart below.
What Is the ARS Pharmaceuticals Inc Stock Price Today?
The ARS Pharmaceuticals Inc stock price today is 5.82.
What Is the Stock Symbol for ARS Pharmaceuticals Inc?
The stock symbol for ARS Pharmaceuticals Inc is "SPRY."
What Stock Exchange Does ARS Pharmaceuticals Inc Trade On?
ARS Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is ARS Pharmaceuticals Inc a Good Stock to Buy?
Determining whether ARS Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SPRY quote. (ISIN: US82835W1080)
What Is the ARS Pharmaceuticals Inc Stock Price Today?
The ARS Pharmaceuticals Inc stock price today is 5.82.
What Is the Stock Symbol for ARS Pharmaceuticals Inc?
The stock symbol for ARS Pharmaceuticals Inc is "SPRY."
What Stock Exchange Does ARS Pharmaceuticals Inc Trade On?
ARS Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is ARS Pharmaceuticals Inc a Good Stock to Buy?
Determining whether ARS Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SPRY quote. (ISIN: US82835W1080)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.75
6.00
52 wk Range
4.91
13.15
SPRY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.756.00
52 wk Range
4.9113.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SPRY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
23.25
Upside
+299.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 23.25
(+299.48% Upside)
ARS Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- ARS Pharmaceuticals reported Q2 2026 revenue of $33.7M, beating estimates of $31.54M by 6.9%, though shares fell 15.58% to $5.15 after hours.
- Neffy generated $26.2M in net product revenue with U.S. market share doubling to 5% from 2.5% year-over-year, reaching 8% in targeted accounts.
- Company announced over 40% cut in cash-based SG&A and R&D spending for H2 2026, targeting $100M-$110M to reach cash flow breakeven by end of 2027.
- Operating expenses of $95.1M far exceeded revenue; gross margin stood at 62% with management expecting improvement as manufacturing scales.
- CSU program interim data readout delayed to Q1 2027 from late 2026; CEO emphasized shift to targeted provider engagement over broad consumer advertising.
Last Updated: 2026-08-13, 05:16 p/m
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-0.63 / -0.50
Revenue / Forecast
33.66M / 31.54M
Compare SPRY to Peers and Sector
Metrics to compare | SPRY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −1.5x | −0.4x | |
PEG Ratio | 0.01 | −0.13 | 0.00 | |
Price/Book | 46.3x | 3.1x | 2.6x | |
Price / LTM Sales | 4.9x | 6.4x | 3.1x | |
Upside (Analyst Target) | 295.2% | 73.9% | 49.0% | |
Fair Value Upside | Unlock | 1.6% | 7.1% | Unlock |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the ARS Pharmaceuticals (SPRY) Stock Price Today?
The ARS Pharmaceuticals stock price today is 5.82 USD.
What Stock Exchange Does ARS Pharmaceuticals Trade On?
ARS Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for ARS Pharmaceuticals?
The stock symbol for ARS Pharmaceuticals is "SPRY."
What Is the ARS Pharmaceuticals Market Cap?
As of today, ARS Pharmaceuticals market cap is 578.78M USD.
What Is ARS Pharmaceuticals's Earnings Per Share (TTM)?
The ARS Pharmaceuticals EPS (TTM) is -2.18.
When Is the Next ARS Pharmaceuticals Earnings Date?
ARS Pharmaceuticals will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is SPRY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has ARS Pharmaceuticals Stock Split?
ARS Pharmaceuticals has split 0 times.
How Many Employees Does ARS Pharmaceuticals Have?
ARS Pharmaceuticals has 198 employees.
What is the current trading status of ARS Pharmaceuticals (SPRY)?
As of Sep 03, 2026, ARS Pharmaceuticals (SPRY) is trading at a price of 5.82 USD, with a previous close of 5.82 USD. The stock has fluctuated within a day range of 5.75 USD to 6.00 USD, while its 52-week range spans from 4.91 USD to 13.15 USD.
What Is ARS Pharmaceuticals (SPRY) Price Target According to Analysts?
The average 12-month price target for ARS Pharmaceuticals is 23.25 USD, with a high estimate of 30 USD and a low estimate of 17 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +299.48% Upside potential.
What Is the SPRY After Hours Price?
SPRY's last after hours stock price is 5.85 USD, the stock has decreased by 0.03, or 0.52%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.